journal article·2019-07-03

Maximizing RNA Loading for Gene Silencing Using Porous Silicon Nanoparticles

Terence Tieu, Sameer Dhawan, V. Haridas, Lisa M. Butler, Helmut Thissen, Anna Cifuentes-Rius, Nicolas H. Voelcker

ACS Applied Materials & Interfaces· Volume 11· Issue 26
Publisher page

Abstract

Gene silencing by RNA interference is a powerful technology with broad applications. However, this technology has been hampered by the instability of small interfering RNA (siRNA) molecules in physiological conditions and their inefficient delivery into the cytoplasm of target cells. Porous silicon nanoparticles have emerged as a potential delivery vehicle to overcome these limitations-being able to encapsulate RNA molecules within the porous matrix and protect them from degradation. Here, key variables were investigated that influence siRNA loading into porous silicon nanoparticles. The effect of modifying the surface of porous silicon nanoparticles with various amino-functional molecules as well as the effects of salt and chaotropic agents in facilitating siRNA loading was examined. Maximum siRNA loading of 413 μg/(mg of porous silicon nanoparticles) was found when the nanoparticles were modified by a fourth generation polyamidoamine dendrimer. Low concentrations of urea or salt increased loading capacity: an increase in RNA loading by 19% at a concentration of 0.05 M NaCl or 21% at a concentration of 0.25 M urea was observed when compared to loading in water. Lastly, it was demonstrated that dendrimer-functionalized nanocarriers are able to deliver siRNA against ELOVL5, a target for the treatment of advanced prostate cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, 381 Royal Parade, Parkville, Victoria 3052, Australia

CSIRO Manufacturing, Bayview Avenue, Clayton, Victoria 3168, Australia

Department of Chemistry, Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, India

Adelaide Medical School & Freemasons Foundation Centre for Men’s Health, University of Adelaide, Adelaide, South Australia 5005, Australia

South Australian Health & Medical Research Institute, Adelaide, South Australia 5001, Australia

Melbourne Centre for Nanofabrication, Victorian Node of the Australian National Fabrication Facility, 151 Wellington Road, Clayton, Victoria 3168, Australia

Funding

Prostate Cancer Foundation of Australia · Movember Foundation · National Health and Medical Research Council · Commonwealth Scientific and Industrial Research Organisation

References (46)

Show source-provided references
1. 10.1016/j.biomaterials.2013.04.06010.1016/j.biomaterials.2013.04.060 ↗
2. 10.1038/nrd274210.1038/nrd2742 ↗
3. 10.1016/j.addr.2009.04.01810.1016/j.addr.2009.04.018 ↗
4. 10.1016/j.addr.2016.06.01110.1016/j.addr.2016.06.011 ↗
5. 10.1016/j.addr.2015.10.00910.1016/j.addr.2015.10.009 ↗
6. 10.1038/nrg376310.1038/nrg3763 ↗
7. 10.1146/annurev-bioeng-071813-10493810.1146/annurev-bioeng-071813-104938 ↗
8. 10.1002/smll.20110076110.1002/smll.201100761 ↗
9. 10.1021/nn203745n10.1021/nn203745n ↗
10. 10.1073/pnas.162087411410.1073/pnas.1620874114 ↗
11. 10.1038/nnano.2014.8410.1038/nnano.2014.84 ↗
12. 10.1002/adma.20140387710.1002/adma.201403877 ↗
13. 10.1021/nl900979310.1021/nl9009793 ↗
14. 10.1039/C5BM00204D10.1039/C5BM00204D ↗
15. 10.1002/smll.20150198510.1002/smll.201501985 ↗
16. 10.1021/acsami.7b0067710.1021/acsami.7b00677 ↗
17. 10.1038/ncomms1513010.1038/ncomms15130 ↗
18. 10.1021/acsbiomaterials.6b0055010.1021/acsbiomaterials.6b00550 ↗
19. 10.1158/0008-5472.CAN-09-393110.1158/0008-5472.CAN-09-3931 ↗
20. 10.1039/C6NH00082G10.1039/C6NH00082G ↗
21. 10.1002/adma.20160063410.1002/adma.201600634 ↗
22. 10.1002/adtp.20180009510.1002/adtp.201800095 ↗
23. 10.1002/adma.20160164610.1002/adma.201601646 ↗
24. 10.1002/adfm.20140341410.1002/adfm.201403414 ↗
25. 10.1002/smll.20170120110.1002/smll.201701201 ↗
26. 10.1002/smll.20090062110.1002/smll.200900621 ↗
27. 10.2217/nnm-2018-003410.2217/nnm-2018-0034 ↗
28. 10.1016/j.tetlet.2007.05.02310.1016/j.tetlet.2007.05.023 ↗
29. 10.1039/C0NJ00544D10.1039/C0NJ00544D ↗
30. 10.1002/cbic.20180010110.1002/cbic.201800101 ↗
31. 10.1038/s41467-018-04390-710.1038/s41467-018-04390-7 ↗
32. 10.1021/cr960427h10.1021/cr960427h ↗
33. 10.1006/jmbi.2000.389410.1006/jmbi.2000.3894 ↗
34. 10.1002/prot.2062610.1002/prot.20626 ↗
35. Ingram L. O. · J. Bacteriol. · 1981 · 146 · 33110.1128/jb.146.1.331-336.1981 ↗
36. 10.1021/ac061358210.1021/ac0613582 ↗
37. 10.1021/ac000662710.1021/ac0006627 ↗
38. 10.1021/jp210769q10.1021/jp210769q ↗
39. 10.1021/ja807887g10.1021/ja807887g ↗
40. 10.1016/j.jconrel.2012.07.00610.1016/j.jconrel.2012.07.006 ↗
41. 10.1002/adhm.20140023510.1002/adhm.201400235 ↗
42. 10.1016/j.nano.2014.03.00610.1016/j.nano.2014.03.006 ↗
43. 10.1021/ma035629b10.1021/ma035629b ↗
44. 10.1016/j.omtn.2019.03.00410.1016/j.omtn.2019.03.004 ↗
45. 10.18632/oncotarget.97510.18632/oncotarget.975 ↗
46. 10.1021/acsami.7b0403810.1021/acsami.7b04038 ↗